Biopharma's Daily Dose.
Why we exist
Most people in this industry are not under-informed. They are over-supplied.
The headlines arrive faster than anyone can read them. The press releases all sound approved. Somewhere between the deal alerts and the earnings recaps, the thing you actually needed goes missing. You finish the morning knowing what happened and still not knowing what to do about it.
Capsul closes that gap.
Who we write for
The people who shape the industry, not the ones watching it.
Capsul is built for the professionals who shape the decisions the industry makes every day: which partnerships to pursue, which data to take seriously, which regulatory signal to move on before everyone else does.
We write for people who read the news to decide something, and who are often already in the room for part of the story. Our job is to tell them the rest.
How it works
One dose, taken whole.
We are not an aggregator. We do not tease, and we do not send you elsewhere. Every edition is complete in itself. You finish knowing what moved, why it moved, and what to watch, without clicking a single link.
The constraint is your time, which we respect more than our own word count. Six minutes between meetings, and you walk away smarter than you sat down.
What you're getting
We tell you what the announcement was trying not to.
We have read enough regulatory decisions to know what the FDA is saying between the lines, and watched enough deals collapse to recognize a distress signal dressed as an announcement. When a company calls a missed endpoint "consistent with prior data," we tell you that is one way to describe it.
The best sentence in a Capsul edition is often the one a corporate communications team would never have approved.
The voice
One standard, every edition, whoever is writing.
Capsul holds a single editorial register no matter whose name is on the edition. Behind every byline sits a newsroom with decades of pattern recognition across global markets, dealmaking, clinical development, and the regulatory machinery of the FDA, EMA, and MHRA.
Who's behind it
The resources are Norstella's. The judgment is the newsroom's.
Capsul is published by Norstella's News & Insights division, the team of reporters and editors behind the industry's most trusted publications: Pink Sheet, Scrip, In Vivo, Medtech Insight, Generics Bulletin and HBW Insight. Read us because the intelligence is good and the writing respects you.
Open it tomorrow. Then open it the day after. That is the only test that matters.